Refine
Has Fulltext
- yes (361)
Year of publication
Document Type
- Journal article (323)
- Doctoral Thesis (36)
- Report (2)
Language
- English (361) (remove)
Keywords
- ischemic stroke (26)
- deep brain stimulation (17)
- neuroinflammation (17)
- Fabry disease (16)
- Parkinson's disease (16)
- multiple sclerosis (16)
- Parkinson’s disease (15)
- Medizin (12)
- stroke (12)
- inflammation (11)
- neuropathic pain (11)
- pain (8)
- subthalamic nucleus (8)
- biomarker (7)
- dopamine (7)
- neurology (7)
- B cells (6)
- Maus (6)
- acute ischemic stroke (6)
- antibodies (6)
- cytokines (6)
- depression (6)
- dystonia (6)
- fibromyalgia syndrome (6)
- macrophages (6)
- mouse model (6)
- neurodegeneration (6)
- neuropathy (6)
- Entzündung (5)
- MS (5)
- Neurodegeneration (5)
- blood-brain barrier (5)
- movement disorders (5)
- neuroprotection (5)
- small fiber neuropathy (5)
- traumatic brain injury (5)
- B7-H1 (4)
- Charcot-Marie-Tooth (4)
- GFAP (4)
- MRI (4)
- Myelin (4)
- Pain (4)
- Schlaganfall (4)
- blood–brain barrier (4)
- disease (4)
- factor XII (4)
- gait initiation (4)
- immunohistochemistry (4)
- macrophage (4)
- magnetic resonance imaging (4)
- mechanical thrombectomy (4)
- middle cerebral artery occlusion (4)
- mutation (4)
- myelin (4)
- platelets (4)
- thrombo-inflammation (4)
- tremor (4)
- walking (4)
- COVID-19 (3)
- EAE (3)
- Fabry-associated pain (3)
- Fibromyalgie (3)
- Gehirn (3)
- HBMEC (3)
- Immunsystem (3)
- Inflammation (3)
- Makrophage (3)
- Mice (3)
- Multiple sclerosis (3)
- Neuroinflammation (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- Parkinson disease (3)
- Parkinson-Krankheit (3)
- T-Lymphozyt (3)
- T-lymphocytes (3)
- Ureaplasma parvum (3)
- adaptive immune system (3)
- animal models (3)
- anxiety (3)
- autoantibodies (3)
- basal ganglia (3)
- biomarkers (3)
- brain (3)
- cerebellar tDCS (3)
- cerebral ischemia (3)
- cervical dystonia (3)
- children (3)
- chronic pain (3)
- closed head injury (3)
- criteria (3)
- dementia (3)
- enzyme replacement therapy (3)
- essential tremor (3)
- experimental autoimmune encephalomyelitis (3)
- expression (3)
- gait analysis (3)
- gene expression (3)
- genetics (3)
- immune cells (3)
- immune system (3)
- inflammasome (3)
- kinematics (3)
- length of stenosis (3)
- local field potentials (3)
- lymphocytes (3)
- mesencephalic locomotor region (3)
- mice (3)
- microRNA (3)
- neuroimmunology (3)
- neutrophils (3)
- photothrombotic stroke (3)
- polyneuropathy (3)
- quality of life (3)
- regulatory T cells (3)
- skin punch biopsy (3)
- tMCAO (3)
- therapy (3)
- tight junctions (3)
- transplantation (3)
- trial (3)
- ALS (2)
- Alzheimer’s disease (2)
- Antikörper (2)
- Autoantibodies (2)
- B-lymphocytes (2)
- Biomarker (2)
- Cerebrospinal fluid (2)
- Charcot-Marie-Syndrom (2)
- Charcot-Marie-Tooth disease (2)
- DYT1 (2)
- Diagnosis (2)
- ELISPOT (2)
- Entmarkung (2)
- Enzyme replacement therapy (2)
- Fabry (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fabry-Krankheit (2)
- Fc-receptor (2)
- Fibromyalgia (2)
- Fibromyalgia syndrome (2)
- Glatiramer acetate (2)
- Guillain-Barre-Syndrome (2)
- Ischemic stroke (2)
- Langerhans cells (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- Macrophage (2)
- Mechanisms (2)
- Multiple Sklerose (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- NEUROWIND (2)
- NLRP3 (2)
- NOAC (2)
- Nervendegeneration (2)
- Neuronal ceroid lipofuscinosis (2)
- Neuropathie (2)
- Neuropathy (2)
- Outcome survey (2)
- PET (2)
- Peripheral nervous system (2)
- Peripheres Nervensystem (2)
- Schwann cell (2)
- T cells (2)
- T lymphocytes (2)
- Tourette syndrome (2)
- Treatment (2)
- Ultraschall (2)
- Ureaplasma urealyticum (2)
- Zentralnervensystem (2)
- accuracy (2)
- aging (2)
- amyotrophic-lateral-sclerosis (2)
- atrial fibrillation (2)
- autoantibody (2)
- autoimmunity (2)
- base of support (2)
- beta oscillations (2)
- binding (2)
- biopsy (2)
- blood brain barrier (2)
- blood flow (2)
- blood pressure (2)
- c-Fos (2)
- caregiver burden (2)
- carotid atherosclerosis (2)
- carotid stenosis (2)
- carotid ultrasound (2)
- central nervous system (2)
- cerebral autoregulation (2)
- cerebrovascular disorders (2)
- chronic cerebrovascular disease (2)
- cognitive impairment (2)
- colony-stimulating factor (2)
- complement (2)
- contact-kinin system (2)
- corneal confocal microscopy (2)
- degeneration (2)
- degree of stenosis (2)
- demyelination (2)
- diagnosis (2)
- diagnostic markers (2)
- differential diagnosis (2)
- disability (2)
- diseases of the nervous system (2)
- echocardiography (2)
- edema (2)
- electrophysiology (2)
- endoglin (2)
- endothelial cells (2)
- experimental stroke (2)
- fibromyalgia (2)
- freezing of gait (2)
- gait (2)
- gene (2)
- generalized cerebral edema (2)
- glial fate modulation (2)
- globotriaosylceramide (2)
- glycoprotein receptor Ib (2)
- guidelines (2)
- hearing loss (2)
- heart failure (2)
- hypoxia (2)
- immunomodulation (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- ion channels (2)
- ischemic penumbra (2)
- lesions (2)
- leukocytes (2)
- machine learning (2)
- major depression (2)
- meningitis (2)
- miR-21 (2)
- miRNA (2)
- microglia (2)
- mitochondria (2)
- mortality (2)
- mouse models (2)
- multiple system atrophy (2)
- multiple-sclerosis (2)
- nerve fibers (2)
- neurofilament light chain (2)
- neurological disorders (2)
- neurons (2)
- opioids (2)
- outcomes (2)
- parkinson's disease (2)
- pathogenesis (2)
- peripheral nervous system (2)
- photothrombosis (2)
- predictive value (2)
- protein (2)
- randomized controlled trial (2)
- rat (2)
- relapse (2)
- renal system (2)
- resting tremor (2)
- reversible posterior leukoencephalopathy syndrome (2)
- second hit (2)
- skin biopsy (2)
- spinal cord (2)
- split-belt treadmill (2)
- striatum (2)
- synaptic vesicles (2)
- thrombosis (2)
- transient ischemic attack (2)
- transient middle cerebral artery occlusion (2)
- velocity (2)
- voluntary movement (2)
- von Willebrand factor (2)
- 2B (1)
- 3D fluoroscopy (1)
- 3D structure (1)
- 3D-Struktur (1)
- 5IA-SPECT (1)
- 65-kda isoform (1)
- A-delta fibers (1)
- A53T (1)
- ADHD (1)
- ALS mimic (1)
- ALS treatment (1)
- ALSIN gene (1)
- APERIO (1)
- APERIO Hybrid (1)
- ASC (1)
- Adaptive cell transfer (1)
- Adaptives Immunsystem (1)
- Adaptorproteine (1)
- Adult patients (1)
- Affekt (1)
- Agalsidase beta (1)
- Agalsidase beta therapy (1)
- Alemtuzumab (1)
- Alpha galactosidase (1)
- Altern (1)
- Alzheimer disease (1)
- Alzheimer’s dementia (1)
- Amplitude (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- Animal models (1)
- Antibody index (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Apoptosis (1)
- Approved immunomodulators (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Arterial Diameters (1)
- Arterial water (1)
- Ataxia (1)
- Atrial fibrillation (1)
- Autoantigen (1)
- Autoimmunität (1)
- Axon (1)
- Axon degeneration (1)
- Axonal degeneration (1)
- Azathioprine (1)
- Aδ- and C-fibers (1)
- B-Lymphocyten (1)
- BB/OKL rats (1)
- Barkhof criteria (1)
- Basal Ganglia (1)
- Basalganglien (1)
- Beta-glucocerebrosidase (1)
- Biopsie (1)
- Braak (1)
- Brain (1)
- Brain atrophy (1)
- Brain edema (1)
- Brain ischemia (1)
- Brain-derived neurotrophic factor (1)
- Brainstem encephalitis (1)
- C.376A>G (p.S126G) (1)
- C1-inhibitor (1)
- C57BL/6 mice (1)
- CCI (1)
- CCS (1)
- CD105 (1)
- CD133 (1)
- CD52 (1)
- CIDP (1)
- CLN3 (1)
- CMV (1)
- CNS (1)
- CNS Myelination (1)
- CNS disease (1)
- CNS imaging (1)
- CNS integrity (1)
- COMPLEX 1 (1)
- COU254 (1)
- CRPS (1)
- CSF (1)
- CSF-1 Rezeptor (1)
- CSF-1 receptor (1)
- CSVD (1)
- CXCL4 (1)
- CXCL5 (1)
- CXCL7 (1)
- CXCL8 (1)
- CXCR2 (1)
- Ca2+ homeostasis (1)
- Ca2+ ion analysis (1)
- Ca2+ leak (1)
- Ca2+ oscillation (1)
- Capsaicin receptor (1)
- Carotisstenose (1)
- Caspase (1)
- Caspr1 (1)
- Cell Index (1)
- Cell therapy (1)
- Cell-based assays (1)
- Central Nervous System (1)
- Cerebellitis (1)
- Cerebral blood flow (1)
- Cerebral small vessel disease (1)
- Cerebral vasospasm (1)
- Cerebral-ischemia (1)
- Charcot-Marie-Tooth syndrom (1)
- Charcot–Marie–Tooth disease (1)
- Charcot–Marie–Tooth disease type 1A (1)
- Chemokine (1)
- Chemokine Receptor (1)
- Chemokinrezeptors (1)
- CholinomiRs (1)
- Chronic heart failure (1)
- Chronic neuropathic pain (1)
- Chronischer Schmerz (1)
- Cisterna magna (1)
- Clinical manifestations (1)
- Clinically silent stroke (1)
- Coefficient (1)
- Cognitive behavior (1)
- Cognitive decline (1)
- Cold (1)
- Computertomographie (1)
- Contactin 1 (1)
- Corneal confocal microscopy (1)
- Cortactin (1)
- Cortico-striatal projection neurons (1)
- Crespi effect (1)
- Cytokine (1)
- Cytokines (1)
- D313Y genotype (1)
- DARPA (1)
- DBS biomarkers (1)
- DBS programming (1)
- DOPA-responsive-dystonia (1)
- DYT-TOR1A (1)
- Deflazacort (1)
- Degeneration (1)
- Delphi procedure (1)
- Demenz (1)
- Demyelinating peripheral neuropathy (1)
- Demyelination (1)
- Demyelinisierung (1)
- Devic Maus (1)
- Devic mice (1)
- Devic’s syndrome (1)
- Diabetes mellitus (1)
- Diabetic polyneuropathy (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Disease (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Dose reduction (1)
- Double hemorrhage model (1)
- Duchenne dystrphy (1)
- Durchblutung (1)
- Dystonia (1)
- Dystonie (1)
- EEG data (1)
- ER Ca2+ imaging (1)
- ER Ca2+ store (1)
- ERK1/2 (1)
- ERT (1)
- Edema (1)
- El Escorial (1)
- Electrophysiology (1)
- Elektrophysiologie (1)
- Embryonalentwicklung (1)
- Emotionales Verhalten (1)
- English version (1)
- Entzündungsreaktion (1)
- Epilepsy (1)
- Epitop (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Evoked potentials (1)
- Experimental stroke (1)
- Expression (1)
- F-18-FDG PET (1)
- FOSMN (1)
- FP-CIT SPECT (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Fabry’s disease (1)
- Facial nerve palsy (1)
- Factor messenger-RNA (1)
- Fc-Rezeptor (1)
- Fibroblasten (1)
- Fibroblasts (1)
- Frabin/Fgd4 (1)
- GABAergic neurons (1)
- GCH1 (1)
- GFAP-astrocytopathies (1)
- GLA KO mouse model (1)
- GRAID (1)
- Gait initiation (1)
- Gene-expression (1)
- Genmutation (1)
- Gland (1)
- Glial fibrillary acidic protein (1)
- Glioblastoma (1)
- Glioma stem cells (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barré syndrome (1)
- Guillain-Barré-Syndrom (1)
- HLA-G (1)
- HMGB1 (1)
- HRUS (1)
- Haut (1)
- Hautzelle (1)
- Head-injury (1)
- Hearing loss (1)
- Heat Hyperalgesia (1)
- Hemodynamic depression (1)
- Hereditary spastic paraplegia (1)
- Hereditäre spastsiche Paraplegie (1)
- Hornhaut (1)
- Hyperalgesia (1)
- IBA-1 (1)
- IENFD (1)
- IL-15 (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- IPND criteria (1)
- IVIg (1)
- Identification (1)
- IgG (1)
- Immune cells (1)
- Immune system (1)
- Immunmodulation (1)
- Immunzellen (1)
- Infections (1)
- Inflamamtion (1)
- Innervation (1)
- Insulin (1)
- IntelliCage (1)
- Interferon beta (1)
- Interleukin-18 (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intravascular coagulation (1)
- Ischemia (1)
- JCV (1)
- K+ channel (1)
- K2P channels (1)
- KCNK5 (1)
- K\(_{2P}\)5.1 (1)
- Kaliumkanal (1)
- Ko-inhibitorischer Signalweg (1)
- Komplement (1)
- L-DOPA (1)
- LI-rTMS (1)
- LIMP-2 (1)
- LSVT-big therapy (1)
- LTD (1)
- Leukemia Inhibitory Factor (1)
- Lewy-like pathology (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Longitudinally extensive transverse myelitis (1)
- Lysosomal storage disease (1)
- MCC950 (1)
- MCP-1 (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMP9 (1)
- MOC fibers (1)
- MOG-IgG (1)
- MPZ (P0) (1)
- MRI criteria (1)
- MSSS (1)
- Macrophages (1)
- Magnetic resonance imaging (1)
- Magnetic-resonance (1)
- Makrophagen (1)
- McDonald criteria (1)
- Mediated Inflammatory Hyperalgesia (1)
- Medium spiny neurons (1)
- Memory dysfunction (1)
- Meningitis (1)
- Merkel cell density (1)
- Mesenchymal stem/stromal cells (1)
- Methotrexate (1)
- Microarray (1)
- Microglia (1)
- Migräne (1)
- Miyoshi myopathy (1)
- Model (1)
- Molecular-weight heparin (1)
- Monopolar depression (1)
- Morbus Fabry (1)
- Motoneuron (1)
- Motoneuronen (1)
- Motor Control (1)
- Motor cortex (1)
- Motor learning (1)
- Motor nerve biopsy (1)
- Motor plasticity (1)
- Motorisches Lernen (1)
- Mucopolysaccharidosis IIIa (1)
- Multiple Sclerosis (1)
- Multiplen Sklerose (1)
- Muster (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelinopathie (1)
- Myelinopathy (1)
- Myelitis (1)
- Myeloma (1)
- NADPH oxidase inhibitors (1)
- NAP-2 (1)
- NETs (1)
- NF-\(\kappa\)B (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NMO-IGG (1)
- NMOSD (1)
- NMR-Tomographie (1)
- NPC1 gene (1)
- NPC2 gene (1)
- NPSI (1)
- NaV1.9 (1)
- Natalizumab (1)
- Natriumkanal (1)
- Nav1.9 (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Nervenbiopsie (1)
- Nervenultraschall (1)
- Nestin (1)
- Neuralgie (1)
- Neurodegenerative Erkrankung (1)
- Neurofascin (1)
- Neurogenic inflammation (1)
- Neurologie (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neuronale Ceroid Lipofuszinose (1)
- Neuropathischer Schmerz (1)
- Neuropsychologie (1)
- Neurotrophic factors (1)
- Neutralisation <Chemie> (1)
- Neutrophil (1)
- NfL (1)
- Niemann–Pick disease type C (1)
- Nodo-parandopathy (1)
- Nucleus subthalamicus (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Optical coherence tomography (1)
- Orai2 (1)
- Oral anticoagulation (1)
- Osteopontin (1)
- Outcome (1)
- PD-1 (1)
- PD-L1 (1)
- PF4 (1)
- PI3K isoforms (1)
- PML (1)
- PMP22 (1)
- PPAR-gamme (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Paradoxical heat sensation (1)
- Parkinson (1)
- Parkinson Krankheit (1)
- Parkinson's Disease (1)
- Parkinsons disease (1)
- Parkionson's disease (1)
- Pathomechanismus (1)
- Perfusion (1)
- Peripheral Inflammation (1)
- Periphere Nerven (1)
- Pharmacological management (1)
- Plasma extravasation (1)
- Plastizität (1)
- Platelets (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Pointing error (1)
- Polyneuropathie (1)
- Pregnancy (1)
- Prodigy (1)
- Progressive supranuclear palsy (1)
- Proprioception (1)
- Psychologische Diagnostik (1)
- QST (1)
- Quality of life (1)
- R-715 (1)
- RECK (1)
- RKIP (1)
- RNA extraction (1)
- Randomized controlled trial (1)
- Randomized controlled-trial (1)
- Rasmussen-Syndrom (1)
- Rat (1)
- Rat Sensory Neurons (1)
- Rats (1)
- Ratte (1)
- Receptors (1)
- Regenerative medicine (1)
- Regulatorische T-Zellen (1)
- Regulatory T cells (1)
- Resilienz (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Rheumatoid-Arthritis (1)
- Rho-GTPase Cdc42 (1)
- Rhombencephalitis (1)
- Richardson-Olszewski-Syndrome (1)
- Rituximab (1)
- Rochester diabetic neuropathy (1)
- SARS-CoV (1)
- SB332235 (1)
- SERCA (1)
- SHRSP (1)
- SNI (1)
- SOD1 mutations (1)
- SPG4 (1)
- SREBP (1)
- STAIR (1)
- STEMI (1)
- Schmerz (1)
- Schwann Zellen (1)
- Schwann cell dedifferentiation (1)
- Schwann cell differentiation (1)
- Schwann cells (1)
- Schwann-Zelle (1)
- Schwann-cells (1)
- Screening questionnaire (1)
- Secondary stroke prevention (1)
- Sensitivity (1)
- Serotonin (1)
- Signaltransduktion (1)
- Silver-syndrome (1)
- Sjorgens-syndrome (1)
- Skelettmuskel (1)
- Skin biopsy (1)
- Small fiber dysfunction (1)
- Small fiber neuropathy (1)
- Small-fiber neuropathy (1)
- Sonic hedgehog (1)
- Sphingosine 1-Phosphate (1)
- Stenosis degree (1)
- Stenosis length (1)
- Stim (1)
- Stimuli (1)
- Striatum (1)
- Stroke (1)
- Stroke unit (1)
- Subarachnoid (1)
- Subarachnoid hemorrhage (1)
- Survey (1)
- Synaptic plasticity (1)
- System involvement (1)
- T cell activation (1)
- T lymphocyte (1)
- T- Lymphozyt (1)
- T-Lymphozyten (1)
- T-PA (1)
- T-cell epitope (1)
- T-cell repertoire (1)
- T-cells (1)
- T-lymphocyte (1)
- T-zell epitope (1)
- T-zell repertoir (1)
- TASK2 (1)
- TBI (1)
- TDMT (1)
- TIMP-1 (1)
- TIND (1)
- TLO (1)
- TMS (1)
- TNF-α (1)
- TNFα (1)
- TOR1A (1)
- TRP Channels (1)
- TSPO (1)
- Tdp-43 (1)
- Therapy (1)
- Thermal Hyperalgesia (1)
- Thrombo-inflammation (1)
- Thrombozyt (1)
- Thrombus (1)
- Thrombus formation (1)
- Training (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Trauma (1)
- Trem2 (1)
- TrkB (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tuberkulose (1)
- Type 1 diabetes (1)
- Ultraschalldiagnostik (1)
- Ureaplasma species (1)
- VCAM-1 (1)
- Vaccination (1)
- Vascular system (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- Western blot (1)
- White matter lesions (1)
- Wingerchuk criteria 2006 and 2015 (1)
- Wissenschaftlicher Nachwuchs (1)
- X-chromosomal inactivation (1)
- XAV-939 (1)
- Zentralnervensystems (1)
- Zonula Occludens-1 (1)
- [18F]FDG positron emission tomography (1)
- acid sphingomyelinase (1)
- activation (1)
- acute lymphoblastic leukaemia (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adhesion molecules (1)
- adrenal medulla (1)
- adult-onset (1)
- advanced therapy medicinal products (1)
- afferents (1)
- age (1)
- aggression (1)
- albumin (1)
- algorithm (1)
- alias pilot trial (1)
- allodynia (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha-galactosidase A (1)
- alpha-synuclein (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amygdala (1)
- amyotrophe Lateralsklerose (1)
- amyotrophic lateral sclerosis (1)
- amyotrophic lateral sclerosis (ALS) (1)
- analgesia (1)
- analgesic medication (1)
- aneurysm surgery (1)
- angiography (1)
- animal behavior (1)
- animal model (1)
- ankles (1)
- antagomir (1)
- anthropometric measurement (1)
- anthropometric measurements (1)
- anti-aquaporin-4 antibody (1)
- anti-contactin-1 (1)
- antibody (1)
- anticoagulants (1)
- anticoagulation (1)
- antidepressants (1)
- antigen-presenting cells (1)
- apoE (1)
- apoe (1)
- apomorphine (1)
- aquaporin 4 (1)
- aquaporin-4 autoantibodies (1)
- areas (1)
- arm (1)
- artery occlusion (1)
- assistive devices (1)
- association (1)
- association studies in genetics (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrophy Kennedys-disease (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attenuation of disease (1)
- atypical chemokine receptor 3 (1)
- autoantibody (aAb) (1)
- autoantigen (1)
- autoimmune (1)
- autoimmune neuroinflammation (1)
- autoimmunität (1)
- autophagy (1)
- autoradiography (1)
- axon growth (1)
- axon guidance molecules (1)
- axonal damage (1)
- axonal degeneration (1)
- axonal integrity (1)
- axonal transcriptome (1)
- axonal transport (1)
- axonaler Schaden (1)
- axonopathic changes (1)
- back pain (1)
- balance (1)
- barrier (1)
- barrier integrity (1)
- basal forebrain cholinergic neurons (1)
- behavioral disorders (1)
- beta oscillation (1)
- beta power (1)
- bilateral internal carotid artery stenosis (1)
- bilateral motor network (1)
- binding analysis (1)
- biological locomotion (1)
- biopsies (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- blood nerve barrier (1)
- bone-marrow (1)
- botulinum toxin (1)
- bradykinesia (1)
- bradykinin (1)
- brain dynamics (1)
- brain edema (1)
- brain endothelium (1)
- brain metabolic alterations (1)
- brain networks (1)
- brain state (1)
- brain stem (1)
- burning pain (1)
- calpain (1)
- capsaicin (1)
- cardiac imaging (1)
- cardiac magnetic resonance imaging (1)
- cardiovascular disease (1)
- care (1)
- care tempis (1)
- caregiver (1)
- case report (1)
- caudate nucleus (1)
- celiac disease (1)
- cell adhesion (1)
- cell binding assay (1)
- cellular therapy (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- cerebral arteries (1)
- cerebral blood flow (1)
- cerebral microbleeds (1)
- cerebral small vessel disease (1)
- cerebrospinal fluid (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- chemokines (1)
- chitinase-3-like protein 1 (1)
- choline acetyltransferase (1)
- cholinergic activity (1)
- cholinergic system (1)
- chronic constriction nerve injury (CCI) (1)
- chronic kidney disease (1)
- chronic stimulation (1)
- chronic stress (1)
- circuitopathies (1)
- classification (1)
- claudin-1 (1)
- clinical approach (1)
- clinical diagnosis (1)
- clinical neurology (1)
- clinical outcome (1)
- clinical phenotype (1)
- clip control (1)
- closed-loop (1)
- co-inhibitory signalling (1)
- coagulation (1)
- coagulation factor XIIa (1)
- cochlea (1)
- cognitive (1)
- cognitive decline (1)
- cognitive function (1)
- coherence (1)
- coherence analysis (1)
- collagens (1)
- collateral circulation (1)
- colony stimulating factor 1 (1)
- compensatory strategies (1)
- complement deposition (1)
- comprehension (1)
- computed tomography (1)
- computer vision (1)
- consolidation (1)
- contact activation system (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- contrast-enhanced MRI (1)
- conversion (1)
- coordination (1)
- coping (1)
- cortical activation (1)
- cortical excitability (1)
- cortical oscillatory activity (1)
- cortical pathology (1)
- cortical silent period (1)
- crossover trial (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- data filtering (1)
- decreasing autonomy (1)
- deep brain stimulation (DBS) (1)
- deep brain-stimulation (1)
- delayed cerebral infarction (1)
- delays progression (1)
- demography (1)
- demyelinating disease (1)
- demyelinating polyradiculoneuropathy (1)
- dendric cells (1)
- design (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diabetic neuropathy (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diagnostic medicine (1)
- diagnostics (1)
- diffuse (1)
- digital medicine (1)
- dimethyl fumarate (1)
- directional deep brain stimulation (1)
- disease model (1)
- disease progression (1)
- disease severity (1)
- disease-modifying therapy (1)
- disorder (1)
- domain potassium channels (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- drug (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- early-onset isolated dystonia (1)
- edoxaban (1)
- effects (1)
- efficacy (1)
- ejection fraction (1)
- electromyography (1)
- element (1)
- embolic stroke (1)
- emotion (1)
- emulsions (1)
- encephalitis (1)
- endothelin-1 (1)
- endotheliopathy (1)
- enteropathy (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- epitope (1)
- event-related desynchronization (1)
- exercise (1)
- exome sequencing (1)
- experimental (1)
- experimental autoimmune neuritis (1)
- experimental design (1)
- expert opinion (1)
- extensiv transverse myelitis (1)
- eye movement disorders (1)
- facial pain (1)
- factor XI (1)
- familial amyloidotic polyneuropathy (1)
- family caregiver (1)
- fatigue (1)
- fear (1)
- fear memory (1)
- feasibility (1)
- female Fabry patients (1)
- females (1)
- fibers (1)
- fibroblast (1)
- fibromyalgia sydrome (1)
- fine-mapping (1)
- finger-tapping task (1)
- fingolimod (1)
- flotillin-1 lipid rafts (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- fosfomycin (1)
- free radical scavenger (1)
- freezing of gait (FOG) (1)
- fullerenes (1)
- functional MRI (1)
- functional connectivity (1)
- functional neuroanatomy (1)
- functional status (1)
- fungal infection (1)
- future directions (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait modulation (1)
- gait-phase prediction (1)
- galactomannan (1)
- gender (1)
- gene mutations (1)
- gene variant (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- gene-environmental interaction (1)
- generalized cerebellar atrophy (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glioblastoma multiforme (1)
- globus pallidus (1)
- globus pallidus pars interna (GPi) (1)
- glycation end products (1)
- glycine receptor (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ibα (1)
- granzyme B (1)
- gridle muscular-dystrophy (1)
- growth (1)
- growth pattern (1)
- health behavior (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hemicraniectomy (1)
- hemorrhagic transformation (1)
- hereditary motor and sensory neuropathy (1)
- hereditary spastic paraplegia (1)
- hereditary spastic paraplegia (HSP) (1)
- hernia repair (1)
- hexanucleotide repeat (1)
- high contrast (1)
- hip (1)
- hippocampus (1)
- histology (1)
- homotypic fusion and protein sorting (1)
- hospitals (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human muscle-cells (1)
- human neurons (1)
- humans (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hyperekplexia (1)
- hypothermia (1)
- i.v. thrombolysis (1)
- iPSC (1)
- idiopathic inflammatory myopathies (1)
- image quality (1)
- image-guided programming (1)
- imaging (1)
- immaturity (1)
- immune (1)
- immune-response (1)
- immunofluorescence (1)
- immunoglobulin-G (1)
- in-vivo (1)
- incidence (1)
- increased risk (1)
- induced neural stem cells (1)
- inducible expression (1)
- inertial measurement units (1)
- infantile neuronal ceroid lipofuscinosis (1)
- infarction (1)
- infarction size (1)
- infarction volume (1)
- inflammatory cascades (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- informal care (1)
- informal caregiving (1)
- informed consent (1)
- inherited metabolic disorders (1)
- inherited peripheral neuropathy (1)
- injection site reactions; (1)
- innate immune system (1)
- innervation (1)
- integrin α2 (1)
- integrins (1)
- interference (1)
- interleukin-1 receptor antagonist (1)
- interleukin-8 (1)
- internal carotid artery stenosis (1)
- internet-based intervention (1)
- interval timing (1)
- interview (1)
- intracranial bleeding (1)
- intracranial hemorrhage (1)
- intractable hiccup (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intraoperative (1)
- intrathecal application (1)
- intravenous immunoglobulin (1)
- intravenous thrombolysis (1)
- invasive electric stimulation (1)
- ipsilateral motor evoked potential (1)
- ipsilateral motor network (1)
- iron (1)
- iron dyshomeostasis (1)
- iron oxide nanoparticles (1)
- ischemia (1)
- ischemia/reperfusion injury (1)
- ischemic cascade (1)
- just noticeable difference (JND) (1)
- kallikrein-kinin system (1)
- kallikrein–kinin system (1)
- kinesthesia (1)
- kinin receptor (1)
- kinin receptors (1)
- knees (1)
- large vessel occlusion (1)
- learning (1)
- levodopa-induced dyskinesia (1)
- linkage (1)
- liponeurocytoma (1)
- locomotion (1)
- locomotor adaptation (1)
- locomotor network (1)
- locus coeruleus (1)
- long-term pain (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal dysfunction (1)
- lysosomal enzyme (1)
- lysosomal storage disease (1)
- lyso‐Gb3 (1)
- magnesium (1)
- management (1)
- matrix metalloproteinases (1)
- mechanical energy (1)
- mechanisms (1)
- medial ganglionic eminence (1)
- medulloblastoma (1)
- mental health (1)
- mesenchymal stem and stromal cells (1)
- mesenchymal stem cells (1)
- metaanalysis (1)
- methylphenidate (1)
- miR-182-5p (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- miRNS (1)
- mice impact (1)
- microangiopathy (1)
- microscopy (1)
- microsphere/macrosphere (1)
- microtubules (1)
- midbrain (1)
- migraine (1)
- migraineur (1)
- mixed fiber neuropathy (1)
- mixed methods (1)
- molecular mechanism (1)
- molecular signature (1)
- monocycline (1)
- monocytes (1)
- monomethyl fumarate (1)
- motoneuron (1)
- motoneuron disease (1)
- motor (1)
- motor axonal neuropathy (1)
- motor control (1)
- motor cortex (1)
- motor evoked potential (MEP) (1)
- motor function (1)
- motor learning (1)
- motor neuron disease (1)
- motor neuropathy (1)
- motor proteins (1)
- motor-evoked potentials (MEP) (1)
- mouse (1)
- mouse brain microvascular endothelial cell cultur (1)
- movement (1)
- movements (1)
- multiple sklerosis (1)
- muscle atrophy (1)
- muscle strength (1)
- musical syntax (1)
- musk myasthenia gravis (1)
- myasthenia gravis (1)
- myelin biology and repair (1)
- myelination (1)
- myocardial infarction (1)
- natural history (1)
- near-infrared spectroscopy (1)
- neonatal meningitis (1)
- nerve biopsy (1)
- nerve fibres (1)
- nerve tumor (1)
- nerve-fibers (1)
- nervous system (1)
- nervous-system (1)
- neural apoptosis (1)
- neural biomarkers (1)
- neural stem cell (1)
- neural stem cells (1)
- neuralgia (1)
- neurobehavioural deficits (1)
- neuroborreliosis (1)
- neurocritical care (1)
- neurocytoma (1)
- neurofascin (1)
- neurofilaments (1)
- neuroleukemiosis (1)
- neurological complications (1)
- neurological examination (1)
- neuromelanin (1)
- neuronal apoptosis (1)
- neuronal ceroid lipofuscinosis (1)
- neuronal differentiation (1)
- neuronal network (1)
- neuronal stem cells (1)
- neuronopathy (1)
- neurophysiology (1)
- neuroplasticity (1)
- neuropsychology (1)
- neurorepair (1)
- neuroscience (1)
- neutralization (1)
- neutrophil (1)
- nicotinamide (1)
- nicotinic receptors (1)
- nociceptor sensitization (1)
- nodes of Ranvier (1)
- non-motor features (1)
- nonalcoholic steatohepatitis (1)
- noradrenalin (1)
- norepinephrine (1)
- novo renal transplantation (1)
- nucleus ventralis intermedius (1)
- nystagmus (1)
- object recognition memory (1)
- obstacle avoidance (1)
- occlusion (1)
- oligodendroglia (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- optical coherence tomography (1)
- oscillations (1)
- outcome (1)
- outer hair cell (OHC) (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- p38 mitogen-activated protein kinase (1)
- p57kip2 (1)
- pain pattern (1)
- pain questionnaire (1)
- pain sensation (1)
- pain-associated behavior (1)
- pain-related evoked potentials (1)
- pallidal stimulation (1)
- pandemic (1)
- paranodopathy (1)
- paraparesis (1)
- parkinson disease (1)
- parkinsons disease (1)
- passive transfer (1)
- pathology section (1)
- pathophysilogical mechanisms (1)
- pathophysiology (1)
- pathway analysis (1)
- pathways (1)
- patient reported outcome measures (1)
- patient triage (1)
- pattern (1)
- pedunculopontine nucleus (PPN) (1)
- pegylated insulin-like growth factor 1 (1)
- peptide (1)
- periperal nerve (1)
- peripheral injury (1)
- peripheral nerve involvement (1)
- peripheral nerve trauma (1)
- peripheral nerves (1)
- peripheral nervous-system (1)
- peripheral neuropathy (1)
- permanent and transient middle cerebral artery occlusion (1)
- pet (1)
- ph (1)
- phosphorylated tau protein (1)
- physical activity (1)
- physical therapy modalities (1)
- pilot project (1)
- placebo-controlled (1)
- plaque cross-sectional area (1)
- plasma extravasation (1)
- plasma oxysterols (1)
- plasminogen (1)
- platelet activation (1)
- platelet aggregation (1)
- point-of-care echocardiography (1)
- pointing task (1)
- polymorphism (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- position estimation (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- postherpetic neuralgia (1)
- postural control (1)
- posture (1)
- potassium channels (1)
- potent inducer (1)
- precision medicine (1)
- preclinical research (1)
- prednisone (1)
- prefrontal cortex (1)
- presynaptic inhibition (1)
- preterm birth (1)
- preventive treatment (1)
- prognosis (1)
- progression (1)
- progressive ataxia (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- progressive supranuclear palsy (1)
- proinflammatory cytokine (1)
- protein and mRNA expression (1)
- proteins (1)
- proteolipid protein (1)
- proteolipid protein gene (1)
- proteomics (1)
- psychological support (1)
- psychophysics (1)
- psychosocial resilience (1)
- purmorphamine (1)
- quality (1)
- quality control (1)
- quality of life (QoL) (1)
- quality-control (1)
- quantitative sensory testing (1)
- qutenza (1)
- randomized controlled double-blind study (1)
- rasmussen encephalitis (1)
- rat brain microvascular endothelial cell culture (1)
- rat hepatocytes (1)
- rats (1)
- reach-to-grasp movement (1)
- reaction-time tasks (1)
- receptor (1)
- receptor tyrosine kinase (1)
- recombinant tissue-type plasminogen activator (1)
- recommendations (1)
- recurrence (1)
- reflex (1)
- regional heterogeneity (1)
- regulation (1)
- regulatory cells (1)
- rehabilitation (1)
- reinnervation (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- religiosity (1)
- renal function (1)
- reoxygenation (1)
- reperfusion (1)
- reperfusion injury (1)
- reproducible outcome measure (1)
- resilience (1)
- responsivity (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- rett (1)
- rhythm perception (1)
- risk (1)
- risk factors (1)
- risk of fall (1)
- rt-PA (1)
- scale (1)
- sciatic nerve (1)
- sciatic nerves (1)
- search filter (1)
- secondary infarct growth (1)
- secretome (1)
- segmental centers of mass (1)
- sensory neurons (1)
- serotonin (1)
- serum (1)
- sex addiction (1)
- shedding (1)
- shingles (1)
- signal peptide (1)
- single photon emission computed tomography (SPECT) (1)
- skilled forelimb movements (1)
- skin cells (1)
- skin diseases (1)
- skin tumors (1)
- small fiber pathology (1)
- small vessel disease (1)
- small-fiber neuropathy (1)
- socioeconomic status (1)
- software (1)
- soleus muscles (1)
- soluble endoglin (1)
- somatic resilience (1)
- somatosensory temporal discrimination (1)
- somatosensory-evoked-potentials (1)
- sphingolipids (1)
- spinal cord injury (1)
- spinal muscular atrophy (1)
- spinal-cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stent-retriever device (1)
- steroids (1)
- stiff-person syndrome (SPS) (1)
- stimulation (1)
- store-operated Ca2+ entry (1)
- stress (1)
- stroke care (1)
- stroke unit (1)
- stromal cells (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous injection (1)
- substance-P (1)
- subthalamic nucleus (STN) (1)
- swimming (1)
- switch (1)
- symptom-specific treatment (1)
- synapse (1)
- synaptic transmission (1)
- syndrome (1)
- system (1)
- systematic review (1)
- systemic inflammation (1)
- systems biology (1)
- systolic dysfunction (1)
- target considerations (1)
- task retention (1)
- telemedicine (1)
- telemedicine network (1)
- temporal discrimination threshold (1)
- teriflunomide (1)
- term follow-up (1)
- tetrahydroisoquinoline derivates (1)
- tetraparesis (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombolysis (1)
- thrombus formation (1)
- tics (1)
- time (1)
- time perception (1)
- timing (1)
- tissue-plasminogen activator (1)
- tolerance (1)
- toleranz (1)
- tool (1)
- topography (1)
- torsinA (1)
- transcranial direct current stimulation (1)
- transcranial magnetic simulation (TMS) (1)
- transgenic mouse model (1)
- transient middle cerebral artery (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- transmission electron microscopy (1)
- treatment options (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- treatment-resistant depression (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- troponin (1)
- tuberculous meningitis (1)
- tumor immunity (1)
- ultrasound (1)
- ultrasound imaging (1)
- under-dosing (1)
- up-regulation (1)
- upper limb (1)
- validation (1)
- variants of unknown significance (1)
- vascular dementia (1)
- vascular homeostasis (1)
- vascular permeability (1)
- vasculopathy (1)
- vertebrobasilar insufficiency (1)
- vertigo (1)
- vessel patency (1)
- vestibular (1)
- videooculography (1)
- virtual reality (1)
- visual activity (1)
- visual pathways (1)
- volume regulation (1)
- weight drop (1)
- white blood cells (1)
- white matter disease (1)
- white matter hyperintensities (1)
- white matter lesions (1)
- α-Galactosidase A (1)
- α-synuclein (1)
- α-synuclein-specific T cells (1)
- α‐GalA 3D‐structure (1)
- β-APP (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (361) (remove)
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Politecnico di Milano (1)
- Sahin Lab, F.M. Kirby Neurobiology Center Boston Children’s Hospital, Department of Neurology, Harvard Medical School (1)
- Wurzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Wurzburg, Germany (1)
- Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), University of Würzburg, Würzburg, Germany (1)
The present cumulative dissertation summarizes three clinical studies, which examine
subgroups of patients within the fibromyalgia syndrome (FMS). FMS entails chronic pain and
associated symptoms, and its pathophysiology is incompletely understood (1). Previous studies
show that there is a subgroup of patients with FMS with objective histological pathology of the
small nerve fibers of the peripheral nervous system (PNS). Another subgroup of FMS patients
does not show any signs of pathological changes of the small nerve fibers. The aim of this
dissertation was to compare FMS patients with healthy controls, and these two FMS subgroups
for differences in the central nervous system (CNS) in order to explore possible interactions
between PNS and the CNS. Regarding the CNS, differences of FMS patients with healthy
controls have already been found in studies with small sample sizes, but no subgroups have yet
been identified. Another aim of this thesis was to test whether the subgroups show a different
response to different classes of pain medication. The methods used in this thesis are structural
and functional magnetic resonance imaging (MRI), magnetic resonance diffusion imaging and
magnetic resonance spectroscopy. For the evaluation of clinical symptoms, we used
standardized questionnaires. The subgroups with and without pathologies of the PNS were
determined by skin biopsies of the right thigh and lower leg based on the intraepidermal nerve
fiber density (IENFD) of the small nerve fibers.
1) In the first MRI study, 43 female patients with the diagnosis of FMS and 40 healthy
control subjects, matched in age and body mass index, were examined with different MRI
sequences. Cortical thickness was investigated by structural T1 imaging, white matter integrity
by diffusion tensor imaging and functional connectivity within neuronal networks by functional
resting state MRI. Compared to the controls, FMS patients had a lower cortical volume in
bilateral frontotemporoparietal regions and the left insula, but a higher cortical volume in the
left pericalcarine cortex. Compared to the subgroup without PNS pathology, the subgroup with
PNS pathology had lower cortical volume in both pericalcarine cortices. Diffusion tensor
imaging revealed an increased fractional anisotropy (FA) of FMS patients in corticospinal
pathways such as the corona radiata, but also in regions of the limbic systems such as the fornix
and cingulum. Subgroup comparison again revealed lower mean FA values of the posterior
thalamic radiation and the posterior limb of the left internal capsule in the subgroup with PNS
pathology. In the functional connectivity analysis FMS patients, compared to controls, showed
a hypoconnectivity between the right median frontal gyrus and the posterior cerebellum and
the right crus cerebellum, respectively. In the subgroup comparisons, the subgroup with PNS
pathology showed a hyperconnectivity between both inferior frontal gyri, the right posterior
parietal cortex and the right angular gyrus. In summary, these results show that differences in
brain morphology and functional connectivity exist between FMS patients with and without
PNS pathology. These differences were not associated with symptom duration or severity and,
in some cases, have not yet been described in the context of FMS. The differences in brain
morphology and connectivity between subgroups could also lead to a differential response to
treatment with centrally acting drugs. Further imaging studies with FMS patients should take
into account this heterogeneity of FMS patient cohorts.
2) Following the results from the first MRI study, drug therapies of FMS patients and
their treatment response were compared between PNS subgroups. As there is no licensed drug
for FMS in Europe, the German S3 guideline recommends amitriptyline, duloxetine and
pregabalin for temporary use. In order to examine the current drug use in FMS patients in
Germany on a cross-sectional basis, 156 patients with FMS were systematically interviewed.
The drugs most frequently used to treat pain in FMS were non-steroidal anti-inflammatory
drugs (NSAIDs) (28.9%), metamizole (15.4%) and amitriptyline (8.8%). Pain relief assessed by
patients on a numerical rating scale from 0-10 averaged 2.2 points for NSAIDs, 2.0 for
metamizole and 1.5 for amitriptyline. Drugs that were discontinued for lack of efficacy and not
for side effects were acetaminophen (100%), flupirtine (91.7%), selective serotonin reuptake
inhibitors (81.8%), NSAIDs (83.7%) and weak opioids (74.1%). Patients were divided into
subgroups with and without PNS pathology as determined by skin biopsies. We found no
differences in drug use and effect between the subgroups. Taken together, these results show
that many FMS patients take medication that is not in accordance with the guidelines. The
reduction of symptoms was best achieved with metamizole and NSAIDs. Further longitudinal
studies on medication in FMS are necessary to obtain clearer treatment recommendations.
3) Derived from previous pharmacological and imaging studies (with smaller case
numbers), there is a hypothesis in the FMS literature that hyperreactivity of the insular cortex
may have an impact on FMS. The hyperreactivity seems to be due to an increased concentration
of the excitatory neurotransmitter glutamate in the insular cortex of FMS patients. The
hypothesis is supported by magnetic resonance spectroscopy studies with small number of
cases, as well as results from pharmacological studies with glutamate-inhibiting medication.
Studies from animal models have also shown that an artificially induced increase in glutamate
in the insular cortex can lead to reduced skin innervation. Therefore, the aim of this study was
to compare glutamate and GABA concentrations in the insular cortex of FMS patients with
those of healthy controls using magnetic resonance imaging. There was no significant
difference of both neurotransmitters between the groups. In addition, there was no correlation
between the neurotransmitter concentrations and the severity of clinical symptoms. There
were also no differences in neurotransmitter concentrations between the subgroups with and
without PNS pathology. In conclusion, our study could not show any evidence of a correlation
of glutamate and GABA concentrations with the symptoms of FMS or the pathogenesis of
subgroups with PNS pathologies.
Background
Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke.
Methods
Focal cerebral ischemia was induced in C57Bl/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24 h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO.
Results
Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis.
Conclusions
Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome—even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke.
Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by variants in the gene α-galactosidase A (GLA). As a consequence, the encoded homonymous enzyme GLA is not produced in sufficient amount or does not function properly. Subsequently, globotriaosylceradmide (Gb3), the target substrate of GLA, starts accumulating in several cell types, especially neurons and endothelial cells. FD patients suffer from multiorgan symptoms including cardiomyopathy, nephropathy, stroke, and acral burning pain. It is suggested that the impact of pathological Gb3 accumulation, inflammatory and hypoxic processes, and vasculopathy are contributing to the specific FD pain phenotype. Thus, we investigated the role of inflammation, hypoxia, and vasculopathy on molecular level in dorsal root ganglia (DRG) of the GLA knockout (KO) mouse model. Further, we investigated pain-like characteristics of GLA KO mice at baseline (BS), after capsaicin administration, and after repeated enzyme replacement therapy (ERT) administration for a period of 1.5 years. Acquired data showed disturbances in immune response markers represented by downregulated inflammation-associated genes and lower numbers of CD206+ macrophages in DRG of GLA KO mice. Hypoxic mechanisms were active in DRG of GLA KO mice reflected by increased gene expression of hypoxia- and DNA damage-associated targets, higher numbers of hypoxia-inducible factor 1α-positive (HIF1α+) and carbonic anhydrase 9-positive (CA9+) neurons in DRG of GLA KO mice, and DRG neuronal HIF1α cytosolic-nuclear translocation in GLA KO mice. Vascularization in DRG of GLA KO mice was reduced including lower numbers of blood vessel branches and reduced total blood vessel length. Pain-like behavior of the GLA KO mouse model revealed no mechanical hypersensitivity at BS but age-dependent heat hyposensitivity, which developed also age-matched wild type (WT) mice. Capsaicin administration under isoflurane anesthesia did not elicit the development of nocifensive behavior in GLA KO mice after mechanical or heat stimulation. Repeated ERT administration did not show a clear effect in GLA KO mice in terms of restored heat hyposensitivity to BS paw withdrawal latencies. In summary, we demonstrated the impact of disturbed immune response markers, active hypoxic mechanisms, and reduced vascularization on molecular FD pathophysiology.
Spinal muscular atrophy (SMA) is a disabling disease that affects not only the patient’s health-related quality of life (HRQoL), but also causes a high caregiver burden (CGB). The aim of this study was to evaluate HRQoL, CGB, and their predictors in SMA. In two prospective, cross-sectional, and multi-center studies, SMA patients (n = 39) and SMA patient/caregiver couples (n = 49) filled in the EuroQoL Five Dimension Five Level Scale (EQ-5D-5L) and the Short Form Health Survey 36 (SF-36). Caregivers (CGs) additionally answered the Zarit Burden Interview (ZBI) and the Hospital Anxiety and Depression Scale (HADS). Patients were clustered into two groups with either low or high HRQoL (EQ-5D-5L index value <0.259 or >0.679). The latter group was mostly composed of ambulatory type III patients with higher motor/functional scores. More severely affected patients reported low physical functioning but good mental health and vitality. The CGB (mean ZBI = 22/88) correlated negatively with patients’ motor/functional scores and age. Higher CGB was associated with a lower HRQoL, higher depression and anxiety, and more health impairments of the CGs. We conclude that patient and CG well-being levels interact closely, which highlights the need to consider the health of both parties while evaluating novel treatments.
Now that mechanical thrombectomy has substantially improved outcomes after large-vessel occlusion stroke in up to every second patient, futile reperfusion wherein successful recanalization is not followed by a favorable outcome is moving into focus. Unfortunately, blood-based biomarkers, which identify critical stages of hemodynamically compromised yet reperfused tissue, are lacking. We recently reported that hypoxia induces the expression of endoglin, a TGF-β co-receptor, in human brain endothelium in vitro. Subsequent reoxygenation resulted in shedding. Our cell model suggests that soluble endoglin compromises the brain endothelial barrier function. To evaluate soluble endoglin as a potential biomarker of reperfusion (-injury) we analyzed its concentration in 148 blood samples of patients with acute stroke due to large-vessel occlusion. In line with our in vitro data, systemic soluble endoglin concentrations were significantly higher in patients with successful recanalization, whereas hypoxia alone did not induce local endoglin shedding, as analyzed by intra-arterial samples from hypoxic vasculature. In patients with reperfusion, higher concentrations of soluble endoglin additionally indicated larger infarct volumes at admission. In summary, we give translational evidence that the sequence of hypoxia and subsequent reoxygenation triggers the release of vasoactive soluble endoglin in large-vessel occlusion stroke and can serve as a biomarker for severe ischemia with ensuing recanalization/reperfusion.
Gait disturbances are common manifestations of Parkinson’s disease (PD), with unmet therapeutic needs. Inertial measurement units (IMUs) are capable of monitoring gait, but they lack neurophysiological information that may be crucial for studying gait disturbances in these patients. Here, we present a machine learning approach to approximate IMU angular velocity profiles and subsequently gait events using electromyographic (EMG) channels during overground walking in patients with PD. We recorded six parkinsonian patients while they walked for at least three minutes. Patient-agnostic regression models were trained on temporally embedded EMG time series of different combinations of up to five leg muscles bilaterally (i.e., tibialis anterior, soleus, gastrocnemius medialis, gastrocnemius lateralis, and vastus lateralis). Gait events could be detected with high temporal precision (median displacement of <50 ms), low numbers of missed events (<2%), and next to no false-positive event detections (<0.1%). Swing and stance phases could thus be determined with high fidelity (median F1-score of ~0.9). Interestingly, the best performance was obtained using as few as two EMG probes placed on the left and right vastus lateralis. Our results demonstrate the practical utility of the proposed EMG-based system for gait event prediction, which allows the simultaneous acquisition of an electromyographic signal to be performed. This gait analysis approach has the potential to make additional measurement devices such as IMUs and force plates less essential, thereby reducing financial and preparation overheads and discomfort factors in gait studies.
Ureaplasma species (spp.) are considered commensals of the adult genitourinary tract, but have been associated with chorioamnionitis, preterm birth, and invasive infections in neonates, including meningitis. Data on mechanisms involved in Ureaplasma-driven neuroinflammation are scarce. The present study addressed brain inflammatory responses in preterm lambs exposed to Ureaplasma parvum (UP) in utero. 7 days after intra-amniotic injection of UP (n = 10) or saline (n = 11), lambs were surgically delivered at gestational day 128–129. Expression of inflammatory markers was assessed in different brain regions using qRT-PCR and in cerebrospinal fluid (CSF) by multiplex immunoassay. CSF was analyzed for UP presence using ureB-based real-time PCR, and MRI scans documented cerebral white matter area and cortical folding. Cerebral tissue levels of atypical chemokine receptor (ACKR) 3, caspases 1-like, 2, 7, and C–X–C chemokine receptor (CXCR) 4 mRNA, as well as CSF interleukin-8 protein concentrations were significantly increased in UP-exposed lambs. UP presence in CSF was confirmed in one animal. Cortical folding and white matter area did not differ among groups. The present study confirms a role of caspases and the transmembrane receptors ACKR3 and CXCR4 in Ureaplasma-driven neuroinflammation. Enhanced caspase 1-like, 2, and 7 expression may reflect cell death. Increased ACKR3 and CXCR4 expression has been associated with inflammatory central nervous system (CNS) diseases and impaired blood–brain barrier function. According to these data and previous in vitro findings from our group, we speculate that Ureaplasma-induced caspase and receptor responses affect CNS barrier properties and thus facilitate neuroinflammation.
Background
Eye movement abnormalities are commonplace in neurological disorders. However, unaided eye movement assessments lack granularity. Although videooculography (VOG) improves diagnostic accuracy, resource intensiveness precludes its broad use. To bridge this care gap, we here validate a framework for smartphone video-based nystagmography capitalizing on recent computer vision advances.
Methods
A convolutional neural network was fine-tuned for pupil tracking using > 550 annotated frames: ConVNG. In a cross-sectional approach, slow-phase velocity of optokinetic nystagmus was calculated in 10 subjects using ConVNG and VOG. Equivalence of accuracy and precision was assessed using the “two one-sample t-test” (TOST) and Bayesian interval-null approaches. ConVNG was systematically compared to OpenFace and MediaPipe as computer vision (CV) benchmarks for gaze estimation.
Results
ConVNG tracking accuracy reached 9–15% of an average pupil diameter. In a fully independent clinical video dataset, ConVNG robustly detected pupil keypoints (median prediction confidence 0.85). SPV measurement accuracy was equivalent to VOG (TOST p < 0.017; Bayes factors (BF) > 24). ConVNG, but not MediaPipe, achieved equivalence to VOG in all SPV calculations. Median precision was 0.30°/s for ConVNG, 0.7°/s for MediaPipe and 0.12°/s for VOG. ConVNG precision was significantly higher than MediaPipe in vertical planes, but both algorithms’ precision was inferior to VOG.
Conclusions
ConVNG enables offline smartphone video nystagmography with an accuracy comparable to VOG and significantly higher precision than MediaPipe, a benchmark computer vision application for gaze estimation. This serves as a blueprint for highly accessible tools with potential to accelerate progress toward precise and personalized Medicine.
Low-frequency oscillatory patterns of pallidal local field potentials (LFPs) have been proposed as a physiomarker for dystonia and hold the promise for personalized adaptive deep brain stimulation. Head tremor, a low-frequency involuntary rhythmic movement typical of cervical dystonia, may cause movement artifacts in LFP signals, compromising the reliability of low-frequency oscillations as biomarkers for adaptive neurostimulation. We investigated chronic pallidal LFPs with the Percept\(^{TM}\) PC (Medtronic PLC) device in eight subjects with dystonia (five with head tremors). We applied a multiple regression approach to pallidal LFPs in patients with head tremors using kinematic information measured with an inertial measurement unit (IMU) and an electromyographic signal (EMG). With IMU regression, we found tremor contamination in all subjects, whereas EMG regression identified it in only three out of five. IMU regression was also superior to EMG regression in removing tremor-related artifacts and resulted in a significant power reduction, especially in the theta-alpha band. Pallido-muscular coherence was affected by a head tremor and disappeared after IMU regression. Our results show that the Percept PC can record low-frequency oscillations but also reveal spectral contamination due to movement artifacts. IMU regression can identify such artifact contamination and be a suitable tool for its removal.
Highlights
• Beta-Guided programming is an innovative approach that may streamline the programming process for PD patients with STN DBS.
• While preliminary findings from our study suggest that Beta Titration may potentially mitigate STN overstimulation and enhance symptom control,
• Our results demonstrate that beta-guided programming significantly reduces programming time, suggesting it could be efficiently integrated into routine clinical practice using a commercially available patient programmer.
Background
Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for advanced Parkinson's disease (PD). Clinical outcomes after DBS can be limited by poor programming, which remains a clinically driven, lengthy and iterative process. Electrophysiological recordings in PD patients undergoing STN-DBS have shown an association between STN spectral power in the beta frequency band (beta power) and the severity of clinical symptoms. New commercially-available DBS devices now enable the recording of STN beta oscillations in chronically-implanted PD patients, thereby allowing investigation into the use of beta power as a biomarker for DBS programming.
Objective
To determine the potential advantages of beta-guided DBS programming over clinically and image-guided programming in terms of clinical efficacy and programming time.
Methods
We conducted a randomized, blinded, three-arm, crossover clinical trial in eight Parkinson's patients with STN-DBS who were evaluated three months after DBS surgery. We compared clinical efficacy and time required for each DBS programming paradigm, as well as DBS parameters and total energy delivered between the three strategies (beta-, clinically- and image-guided).
Results
All three programming methods showed similar clinical efficacy, but the time needed for programming was significantly shorter for beta- and image-guided programming compared to clinically-guided programming (p < 0.001).
Conclusion
Beta-guided programming may be a useful and more efficient approach to DBS programming in Parkinson's patients with STN-DBS. It takes significantly less time to program than traditional clinically-based programming, while providing similar symptom control. In addition, it is readily available within the clinical DBS programmer, making it a valuable tool for improving current clinical practice.